Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

RU-28253

From Wikipedia, the free encyclopedia

RU-28253
Clinical data
Other namesRU28253; 5-MeO-THPI
Drug classNon-selective serotonin receptor agonist
ATC code
  • None
Identifiers
  • 5-methoxy-3-(1,2,3,6-tetrahydropyridin-5-yl)-1H-indole
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC14H16N2O
Molar mass228.295 g·mol−1
3D model (JSmol)
  • COC1=CC2=C(C=C1)NC=C2C3=CCCNC3
  • InChI=1S/C14H16N2O/c1-17-11-4-5-14-12(7-11)13(9-16-14)10-3-2-6-15-8-10/h3-5,7,9,15-16H,2,6,8H2,1H3
  • Key:WBJMGSVSSCEGFV-UHFFFAOYSA-N

RU-28253, also known as 5-MeO-THPI, is a non-selective serotonin receptor agonist of the tryptamine, 5-methoxytryptamine, and tetrahydropyridinylindole families.[1][2][3][4] It is a tetrahydropyridylindole and a conformationally constrained analogue of 5-MeO-DMT.[2][3]

The drug shows high affinity for the serotonin 5-HT1A receptor (Ki = 5.7 nM) and lower affinity for the serotonin 5-HT2A receptor (Ki = 230 nM).[2] Its affinities for these receptors were higher than those of dimethyltryptamine (DMT).[2] RU-28253 is described as a potent agonist of the serotonin 5-HT1 and 5-HT2 receptors,[5] including of the serotonin 5-HT1B receptor,[6] and is also an agonist of the serotonin 5-HT4 receptor.[3][7]

RU-28253 was first described in the scientific literature by 1983.[8][9][2]

See also

[edit]

References

[edit]
  1. Kitson SL (2007). "5-hydroxytryptamine (5-HT) receptor ligands". Current Pharmaceutical Design. 13 (25): 2621–2637. doi:10.2174/138161207781663000. PMID 17897004.
  2. 1 2 3 4 5 Taylor EW, Nikam S, Weck B, Martin A, Nelson D (October 1987). "Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites". Life Sciences. 41 (16): 1961–1969. doi:10.1016/0024-3205(87)90749-1. PMID 3657392.
  3. 1 2 3 Dean RL (1999). Conformationally and rotationally restricted analogs of 5-hydroxytryptamine (Ph.D. thesis). University of Arizona. ProQuest 304510409. Retrieved 1 April 2025. Tetrahydropyridylindoles have been of interest since the initial reports showed that RU 24969 (6) and RU 28253 (7) had high potency as 5-HT agonists and were able to differentiate between certain 5-HT receptors (Euvard, 1980; Hunt, 1981). [...] RU 28253 acts as an agonist at the 5-HT4 receptor, having selective activity over RU 24969. [...]
  4. Nichols DE, Oberlender R, McKenna DJ (1991). "Stereochemical Aspects of Hallucinogenesis". In Watson RR (ed.). Biochemistry and Physiology of Substance Abuse. Vol. 3. Boca Raton, Fla.: CRC Press. pp. 1–39. ISBN 978-0-8493-4463-3. OCLC 26748320.
  5. Dahlgren T, Dean RL, Gharat LA, Johansson AM, Lambert G, Li HB, et al. (1995). "Synthesis and serotonin receptor binding properties of 5-substituted 3-(1′,2′,5′,6′-tetrahydropyridin-3′-yl) indoles". Bioorganic & Medicinal Chemistry Letters. 5 (24): 2963–2968. doi:10.1016/0960-894X(95)00534-8.
  6. Dumuis A, Bouhelal R, Sebben M, Cory R, Bockaert J (December 1988). "A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system". Molecular Pharmacology. 34 (6): 880–887. doi:10.1016/S0026-895X(25)10130-2. PMID 2849052.
  7. Dumuis A, Ansanay H, Waeber C, Sebben M, Fagni L, Bockaert J (1997). "5-HT4 receptors". Pharmacochemistry Library. Vol. 27. Elsevier. pp. 261–308. doi:10.1016/s0165-7208(97)80017-7. ISBN 978-0-444-82041-9.
  8. Marrs TC (1983). "Poster Communications: Part I: The Actions of Three Mammalian Serotonin Receptor Agonists on Helix Central Neurones". British Journal of Pharmacology. 80 (Suppl): 494P–533P. PMC 2044929.
  9. Taylor EW (1985). The Development of Indoleamine Derivatives (Ph.D. thesis). University of Arizona. ProQuest 303387893. Retrieved 1 April 2025.
[edit]